Ocular Therapeutix announced it plans to accelerate its intended New Drug Application (NDA) for AXPAXLI (OTX-TKI) for the ...

The US Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to EyeYon Medical for its US clinical study of EndoArt, which is currently designated by the FDA ...

Formosa and Rxilient have an exclusive licensing agreement for APP13007 commercialization, including regulatory and sales ...

ViaLase announced the first patient has been treated in its US-based Investigational Device Exemption (IDE) clinical trial ...

PainReform has released details on, and the commencement of, its development plan for OcuRing-K, including an upcoming phase 2 clinical trial. 1 ...

Of the 1000 patients with dry eye symptoms surveyed, 80% stated that “they would try a science-backed eye drop that mimics ...

Iolyx Therapeutics and Laboratoires Théa (Théa), through support from its subsidiary Théa Open Innovation, have entered into ...

The panel reviews the mechanisms, efficacy, and tolerability of novel treatments, including perfluorohexyloctane (Miebo), ...

Experts highlight management nuances in patients with neuropathic pain, post–refractive surgery complications, or contact lens intolerance.

K8, a dual inflammasome inhibitor, is being tested for geographic atrophy in a phase 2 trial involving 30 patients across 9 US centers. Kamuvudines, derived from anti-HIV drugs, retain ...